Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women

Blood

Volumn 89, Issue 8, 1997, Pages 2817-2821

  Rosendaal, F R ^a   Siscovick, D S ^b   Schwartz, S M ^b   Beverly, R K ^b   Psaty, B M ^b   Longstreth Jr , W T ^b   Raghunathan, T E ^b   Koepsell, T D ^b   Reitsma, P H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEART INFARCTION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; VEIN THROMBOSIS;

EID: 0030984288     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.2817     Document Type: Article

References (31)

1. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, Van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
2. Greengard JS, Sun X, Xu X, Fernandez GA, Griffin JH, Evatt B: Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343:1362, 1994
3. Zöller B, Dahlbäck B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536, 1994
4. Voorberg J, Roelse J, Koopman B, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA: Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 343:1535, 1994
5. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004, 1993
6. Koster T, Rosendaal FR, Ronde H de, Briët E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503, 1993
7. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994
8. Dahlbäck B: Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 85:607, 1995
9. Dahlbäck B: Physiological anticoagulation: resistance to activated protein C and venous thromboembolism. J Clin Invest 94:923, 1994
10. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM: Resistance to activated protein C in nine thrombophilic families: interference in a protein S assay. Thromb Haemost 70:1067, 1993
11. Cadroy Y, Sié P, Boneu B: Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 83:2008, 1994
12. Cushman M, Bhushan F, Bovill E, Tracy R: Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 72:647, 1994
13. Halbmayer WM, Haushofer A, Schön R, Fisher M: The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 5:51, 1994
14. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995
15. Griffin JH, Evatt B, Widerman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989, 1993
16. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504, 1995
17. Lindblad B, Svensson PJ, Dahlbäck B: Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 343:917, 1994
18. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 344:952, 1994
19. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I: Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 345:526, 1995
20. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M: Arg506Gln Factor V mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73:558, 1995
21. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F: Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 345:321, 1995
22. Van Bockxmeer FM, Baker RI, Taylor RR: Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1:185, 1995
23. 506 → Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 75:701, 1996
24. Shapiro S, Rosenberg L, Slone D, Kaufman DW, Stolley PD, Miettinen OS: Oral contraceptive use in relation to myocardial infarction. Lancet 1:743, 1979
25. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Tracy RP, Weiler PG for the Cardiovascular Health Study Research Group (CHS): The cardiovascular health study: design and rationale. Ann Epidemiol 1:263, 1991
26. Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J: Random digit dialing in selecting a population-based control group. Am J Epidemiol 120:825, 1984
27. Millar SA, Dijkes DD, Polesky HF: A simple salting out procedure for extracting DNA from nucleated cells. Nucleic Acids Res 16:1215, 1988
28. Rosendaal FR, Bertina RM, Reitsma PH: Evaluation of activated protein C resistance in stored plasma. Lancet 343:1289, 1994
29. Samani NJ, Lodwick D, Martin D, Kimber P: Resistance to activated protein C and risk of premature myocardial infarction. Lancet 344:1709, 1994
30. Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J: Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost 73:402, 1995
31. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344:1453, 1994